Clinical Applications of Molecular Biomarkers in Prostate Cancer

被引：27

作者：

Counago, Felipe ^{[1
,2
,3
]}

Lopez-Campos, Fernando ^{[4
]}

Diaz-Gavela, Ana Aurora ^{[1
,2
,3
]}

Almagro, Elena ^{[5
]}

Fenandez-Pascual, Esau ^{[6
,7
]}

Henriquez, Ivan ^{[8
]}

Lozano, Rebeca ^{[9
,10
]}

Espinos, Estefania Linares ^{[6
,7
]}

Gomez-Iturriaga, Alfonso ^{[11
]}

de Velasco, Guillermo ^{[12
]}

Franco, Luis Miguel Quintana ^{[7
]}

Rodriguez-Melcon, Ignacio ^{[13
]}

Lopez-Torrecilla, Jose ^{[14
]}

Spratt, Daniel E. ^{[15
]}

Guerrero, Luis Leonardo ^{[1
,2
,3
]}

Martinez-Salamanca, Juan Ignacio ^{[6
,16
]}

del Cerro, Elia ^{[1
,2
,3
]}

机构：

[1] Hosp Univ Quironsalud Madrid, Radiat Oncol, Madrid 28223, Spain

[2] Hosp La Luz, Radiat Oncol, Madrid 28003, Spain

[3] Univ Europea Madrid, Clin Dept, Fac Biomed, Madrid 28670, Spain

[4] Hosp Univ Ramon y Cajal, Radiat Oncol, Madrid 28034, Spain

[5] Hosp Univ Quironsalud Madrid, Med Oncol, Madrid 28223, Spain

[6] Univ Francisco Vitoria, Lyx Inst Urol, Madrid 28006, Spain

[7] Univ La Paz, Dept Urol, Madrid 28046, Spain

[8] Hosp Univ St Joan, Radiat Oncol, Reus 43204, Spain

[9] Spanish Natl Canc Res Ctr, Prostate Canc Clin Res Unit, Madrid 28029, Spain

[10] Inst Biomed Res, Genitourinary Canc Traslat Res Grp, Malaga 29010, Spain

[11] Biocruces Heath Res Inst, Cruces Univ Hosp, Baracaldo 48903, Spain

[12] Hosp Univ 12 Octubre, Med Oncol, Madrid 28041, Spain

[13] Hosp Univ Gran Canaria Dr Negrin, Radiat Oncol, Las Palmas Gran Canaria 35010, Spain

[14] Hosp Gen Univ Valencia, Radiat Oncol ERESA, Valencia 46014, Spain

[15] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA

[16] Hosp Univ Puerta Hierro, Dept Urol, Madrid 28222, Spain

来源：

CANCERS | 2020年 / 12卷 / 06期

关键词：

biomarkers; DNA repair; gene panels; genetic testing; germline mutation; precision medicine; prostate cancer; prostate genomics; CYCLE PROGRESSION SCORE; CIRCULATING TUMOR-CELLS; BIOCHEMICAL FAILURE; RISK STRATIFICATION; RADICAL PROSTATECTOMY; GENOMIC CLASSIFIER; RADIATION-THERAPY; BRCA MUTATIONS; GENE FUSIONS; PATIENTS PTS;

D O I：

10.3390/cancers12061550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is clinically relevant molecular heterogeneity in prostate cancer (PCa), but this biological diversity has had only a minimal impact on clinical practice. Treatment outcomes in patients with localised PCa are often highly variable, even among patients stratified to the same risk group or disease state based on standard clinical and pathological parameters. In recent years, the development of gene panels has provided valuable data on the differential expression of genes in patients with PCa. Nevertheless, there is an urgent need to identify and validate prognostic and predictive biomarkers that can be applied across clinical scenarios, ranging from localised disease to metastatic castration-resistant PCa. The availability of such tools would allow for precision medicine to finally reach PCa patients. In this review, we evaluate current data on molecular biomarkers for PCa, with an emphasis on the biomarkers and gene panels with the most robust evidence to support their application in routine clinical practice.

引用

页码：1 / 25

页数：24

共 133 条

[71] Tumour lineage shapes BRCA-mediated phenotypes [J].

Jonsson, Philip ;

Bandlamudi, Chaitanya ;

Cheng, Michael L. ;

Srinivasan, Preethi ;

Chavan, Shweta S. ;

Friedman, Noah D. ;

Rosen, Ezra Y. ;

Richards, Allison L. ;

Bouvier, Nancy ;

Selcuklu, S. Duygu ;

Bielski, Craig M. ;

Abida, Wassim ;

Mandelker, Diana ;

Birsoy, Ozge ;

Zhang, Liying ;

Zehir, Ahmet ;

Donoghue, Mark T. A. ;

Baselga, Jose ;

Offit, Kenneth ;

Scher, Howard I. ;

O'Reilly, Eileen M. ;

Stadler, Zsofia K. ;

Schultz, Nikolaus ;

Socci, Nicholas D. ;

Viale, Agnes ;

Ladanyi, Marc ;

Robson, Mark E. ;

Hyman, David M. ;

Berger, Michael F. ;

Solit, David B. ;

Taylor, Barry S. .

NATURE, 2019, 571 (7766) :576-+

[72] MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis [J].

Kasivisvanathan, V ;

Rannikko, A. S. ;

Borghi, M. ;

Panebianco, V ;

Mynderse, L. A. ;

Vaarala, M. H. ;

Briganti, A. ;

Budaus, L. ;

Hellawell, G. ;

Hindley, R. G. ;

Roobol, M. J. ;

Eggener, S. ;

Ghei, M. ;

Villers, A. ;

Bladou, F. ;

Villeirs, G. M. ;

Virdi, J. ;

Boxler, S. ;

Robert, G. ;

Singh, P. B. ;

Venderink, W. ;

Hadaschik, B. A. ;

Ruffion, A. ;

Hu, J. C. ;

Margolis, D. ;

Crouzet, S. ;

Klotz, L. ;

Taneja, S. S. ;

Pinto, P. ;

Gill, I ;

Allen, C. ;

Giganti, F. ;

Freeman, A. ;

Morris, S. ;

Punwani, S. ;

Williams, N. R. ;

Brew-Graves, C. ;

Deeks, J. ;

Takwoingi, Y. ;

Emberton, M. ;

Moore, C. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1767-1777

[73] Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer [J].

Khan, Salma ;

Jutzy, Jessica M. S. ;

Valenzuela, Malyn May A. ;

Turay, David ;

Aspe, Jonathan R. ;

Ashok, Arjun ;

Mirshahidi, Saied ;

Mercola, Dan ;

Lilly, Michael B. ;

Wall, Nathan R. .

PLOS ONE, 2012, 7 (10)

[74] Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance [J].

Kim, Hyung L. ;

Li, Ping ;

Huang, Huei-Chung ;

Deheshi, Samineh ;

Marti, Tara ;

Knudsen, Beatrice ;

Abou-Ouf, Hatem ;

Alam, Ridwan ;

Lotan, Tamara L. ;

Lam, Lucia L. C. ;

du Plessis, Marguerite ;

Davicioni, Elai ;

Fleshner, Neil ;

Lane, Brian R. ;

Rosso, Ashley E. ;

Davis, John W. ;

Mohler, James L. ;

Trock, Bruce J. ;

Klein, Eric A. ;

Tosoian, Jeffrey J. ;

Hyndman, M. Eric ;

Bismar, Tarek A. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2019, 22 (03) :399-405

[75] A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling [J].

Klein, Eric A. ;

Cooperberg, Matthew R. ;

Magi-Galluzzi, Cristina ;

Simko, Jeffry P. ;

Falzarano, Sara M. ;

Maddala, Tara ;

Chan, June M. ;

Li, Jianbo ;

Cowan, Janet E. ;

Tsiatis, Athanasios C. ;

Cherbavaz, Diana B. ;

Pelham, Robert J. ;

Tenggara-Hunter, Imelda ;

Baehner, Frederick L. ;

Knezevic, Dejan ;

Febbo, Phillip G. ;

Shak, Steven ;

Kattan, Michael W. ;

Lee, Mark ;

Carroll, Peter R. .

EUROPEAN UROLOGY, 2014, 66 (03) :550-560

[76]

Konety Badrinath, 2015, Rev Urol, V17, P231

[77] BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients [J].

Kote-Jarai, Z. ;

Leongamornlert, D. ;

Saunders, E. ;

Tymrakiewicz, M. ;

Castro, E. ;

Mahmud, N. ;

Guy, M. ;

Edwards, S. ;

O'Brien, L. ;

Sawyer, E. ;

Hall, A. ;

Wilkinson, R. ;

Dadaev, T. ;

Goh, C. ;

Easton, D. ;

Goldgar, D. ;

Eeles, R. .

BRITISH JOURNAL OF CANCER, 2011, 105 (08) :1230-1234

[78] Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality [J].

Larranaga, N. ;

Galceran, J. ;

Ardanaz, E. ;

Franch, P. ;

Navarro, C. ;

Sanchez, M. J. ;

Pastor-Barriuso, R. .

ANNALS OF ONCOLOGY, 2010, 21 :iii83-iii89

[79] Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores [J].

Lecarpentier, Julie ;

Silvestri, Valentina ;

Kuchenbaecker, Karoline B. ;

Barrowdale, Daniel ;

Dennis, Joe ;

McGuffog, Lesley ;

Soucy, Penny ;

Leslie, Goska ;

Rizzolo, Piera ;

Navazio, Anna Sara ;

Valentini, Virginia ;

Zelli, Veronica ;

Lee, Andrew ;

Al Olama, Ali Amin ;

Tyrer, Jonathan P. ;

Southey, Melissa ;

John, Esther M. ;

Conner, Thomas A. ;

Goldgar, David E. ;

Buys, Saundra S. ;

Janavicius, Ramunas ;

Steele, Linda ;

Ding, Yuan Chun ;

Neuhausen, Susan L. ;

Hansen, Thomas V. O. ;

Osorio, Ana ;

Weitzel, Jeffrey N. ;

Toss, Angela ;

Medici, Veronica ;

Cortesi, Laura ;

Zanna, Ines ;

Palli, Domenico ;

Radice, Paolo ;

Manoukian, Siranoush ;

Peissel, Bernard ;

Azzollini, Jacopo ;

Viel, Alessandra ;

Cini, Giulia ;

Damante, Giuseppe ;

Tommasi, Stefania ;

Peterlongo, Paolo ;

Fostira, Florentia ;

Hamann, Ute ;

Evans, D. Gareth ;

Henderson, Alex ;

Brewer, Carole ;

Eccles, Diana ;

Cook, Jackie ;

Ong, Kai-ren ;

Walker, Lisa .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (20) :2240-+

[80] Germline BRCA1 mutations increase prostate cancer risk [J].